UROGEN PHARMA (NASDAQ:URGN) – Equities researchers at Oppenheimer Holdings increased their FY2020 earnings per share (EPS) estimates for UROGEN PHARMA in a research note issued to investors on Friday. Oppenheimer Holdings analyst D. Archila now forecasts that the company will earn $0.35 per share for the year, up from their previous forecast of $0.25. Oppenheimer Holdings has a “Outperform” rating and a $32.00 price target on the stock. Oppenheimer Holdings also issued estimates for UROGEN PHARMA’s FY2021 earnings at $2.73 EPS.
URGN has been the topic of a number of other reports. Cowen and Company assumed coverage on UROGEN PHARMA in a report on Tuesday, May 30th. They set an “outperform” rating on the stock. Jefferies Group LLC assumed coverage on UROGEN PHARMA in a report on Tuesday, May 30th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, Raymond James Financial, Inc. assumed coverage on UROGEN PHARMA in a report on Tuesday, May 30th. They set an “outperform” rating and a $25.00 price objective on the stock.
Shares of UROGEN PHARMA (URGN) opened at 17.9477 on Monday. The company’s market capitalization is $214.89 million. The stock’s 50 day moving average price is $17.62 and its 200 day moving average price is $17.35. UROGEN PHARMA has a 12-month low of $13.01 and a 12-month high of $20.02.
About UROGEN PHARMA
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
What are top analysts saying about UROGEN PHARMA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for UROGEN PHARMA and related companies.